MENU
ESTA
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Establishment Labs Holdings (ESTA) Earnings Date & Reports

Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products... Show more

A.I. Advisor
published Earnings

ESTA is expected to report earnings to fall 70.03% to -10 cents per share on March 02

Establishment Labs Holdings ESTA Stock Earnings Reports
Q4'26
Est.
$-0.10
Q3'26
Missed
by $0.08
Q2'26
Missed
by $0.05
Q1'26
Missed
by $0.09
Q4'25
Beat
by $0.13
The last earnings report on October 29 showed earnings per share of -34 cents, missing the estimate of -27 cents. With 229.25K shares outstanding, the current market capitalization sits at 2.00B.
A.I.Advisor
Oct 29, 2026

Establishment Labs Holdings (ESTA) Third Quarter 2026 Earnings Recap: US Expansion Hits a New Gear

Key Takeaways

  • Revenue rose 33.9% year over year to $72.0 million, ahead of the roughly $66.6 million consensus estimate.
  • GAAP (generally accepted accounting principles) net loss narrowed to $10.7 million, or $0.35 per share, versus a loss of $0.38 per share a year earlier.
  • U.S. revenue climbed 119% to $26.0 million, while revenue outside the United States (OUS) grew 9.7% to $46.0 million.
  • Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $6.4 million, and the company posted its first quarter of positive free cash flow at $5.1 million.
  • Management raised full-year 2026 revenue guidance to more than $274 million, up from its prior range of $269 million to $271 million.
  • Adjusted gross margin was 70.8%, and the company guided full-year adjusted gross margin to approximately 70.7%.
  • For more details, explore Major News, Today's Price Move, Price Targets, and Forecast pages.
  • Discover additional market ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Establishment Labs Holdings is a Costa Rica-based medical technology company focused on women's health, breast aesthetics, and breast reconstruction, best known for its Motiva implant portfolio. Its third-quarter report matters because it tests whether the company can convert rapid U.S. market-share gains into improving profitability and cash generation. Heading into the print, investors were watching top-line momentum, gross margin trajectory, and the path toward positive free cash flow. The company entered the quarter having raised guidance in consecutive periods, and the U.S. launch of Motiva and the Preservé minimally invasive platform remained the central growth story. Results delivered record-scale revenue growth and a long-awaited cash-flow milestone, even as one-time charges pressured the reported bottom line.

Reported Results

For the third quarter ended September 30, 2026, Establishment Labs reported revenue of $72.0 million, an increase of 33.9% from $53.8 million in the prior-year period and above the consensus estimate of approximately $66.6 million. U.S. revenue surged 119% to $26.0 million, representing 36.1% of total revenue, while revenue outside the United States rose 9.7% to $46.0 million. The minimally invasive platform generated about $9 million in revenue, up 124% year over year.

GAAP net loss narrowed to $10.7 million, or $0.35 per share, compared with a loss of $11.1 million, or $0.38 per share, a year earlier. The per-share result came in below the consensus estimate of a $0.27 loss, driven largely by below-the-line interest expense and one-time litigation, restructuring, and inventory charges. GAAP gross margin was 69.1%, while adjusted gross margin improved to 70.8%, up 70 basis points year over year on a favorable U.S. and minimally invasive product mix.

Adjusted EBITDA increased to $6.4 million, or 8.9% of revenue, from $1.2 million in the prior-year quarter. The company generated $7.7 million in operating cash flow and $5.1 million in free cash flow, marking its first positive free-cash-flow quarter. Management also raised full-year 2026 revenue guidance to more than $274 million and reiterated an expectation for roughly 25% revenue growth in 2027.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Establishment Labs, the AI Screener offers a structured way to monitor sector momentum and identify comparable opportunities. Consider exploring the AI Screener to refine your own watchlists and research workflow.

Market Reaction and Investor Sentiment

The market's focus was split between the company's accelerating U.S. growth and the headline earnings-per-share miss. While revenue beat expectations by roughly 8%, the $0.35 per-share loss fell short of the consensus $0.27 loss, reflecting interest expense on the company's note payable and one-time litigation, restructuring, and inventory-related charges. Investors appeared to weigh the quality of the operating results more heavily, as adjusted EBITDA expanded, operating leverage improved, and the company delivered its first positive free-cash-flow quarter. The third consecutive full-year revenue guidance increase, along with a reaffirmed expectation for about 25% revenue growth in 2027, reinforced the view that demand momentum remains intact. Sentiment remains balanced against thinner profitability in OUS distributor channels and the company's relatively lean balance sheet.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will likely track whether Establishment Labs can sustain its U.S. adoption momentum while converting that growth into durable profitability and cash generation. Management pointed to an 85% quarter-over-quarter reorder rate among U.S. accounts and more than 2,100 active accounts, suggesting utilization within the existing surgeon base is becoming the key growth lever.

Regulatory and product milestones will also be closely watched. The October FDA (U.S. Food and Drug Administration) approval of additional Motiva implant sizes is expected to be commercially available before year-end, and management is working toward a reconstruction approval targeted for late 2026 or early 2027. The company also plans to expand sizes for its Mia and Preservé minimally invasive products globally.

On the financial side, the full-year adjusted gross margin guidance of approximately 70.7% reflects a higher mix of lower-margin OUS distributor sales, a dynamic worth monitoring. The company reiterated full-year adjusted operating expense guidance of $195 million to $200 million. With the balance sheet still carrying a substantial note payable against $75.8 million in cash, sustained free-cash-flow generation will remain a focal point for investors assessing the company's path toward self-funding growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of medical products

Industry MedicalNursingServices

Industry
Medical Specialties
Address
11401 Century Oaks Terrace
Phone
+1 800 924-5072
Employees
1004
Web
https://establishmentlabs.com